Bevacizumab in colorectal cancer: current and future directions.

Expert review of anticancer therapy

Volumn 12, Issue 10, 2012, Pages 1263-1273

  Yeung, Yvonne ^a   Tebbutt, Niall C ^b  

^a LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; MONOCLONAL ANTIBODY; TUMOR MARKER;

ANIMAL; CLINICAL TRIAL (TOPIC); COLORECTAL TUMOR; DRUG RESISTANCE; HUMAN; METABOLISM; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; CLINICAL TRIALS AS TOPIC; COLORECTAL NEOPLASMS; DRUG RESISTANCE, NEOPLASM; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TUMOR MARKERS, BIOLOGICAL;

EID: 84877094311     PISSN: None     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.12.104     Document Type: Review

References (0)